This Article  • Full text  • PDF  • Correction  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (3)  • Contact me when this article is cited  Related Content  • Related letter  • Related article  • Similar articles in this journal  Topic Collections  • Diabetic Retinopathy  • Alert me on articles by topic

The Diabetes Control and Complications Trial Research Group

Arch Ophthalmol. 1998;116:874-886.

Objectives  To document the frequency, importance of, and risk factors for "early worsening" of diabetic retinopathy in the Diabetes Control and Complications Trial (DCCT).

Methods  The DCCT was a multicenter, randomized clinical trial comparing intensive vs conventional treatment in insulin-dependent diabetic patients who had no to moderate nonproliferative retinopathy. Retinopathy severity was assessed in 7-field stereoscopic fundus photographs taken at baseline and every 6 months. For this study, worsening was defined as progression of 3 steps or more on the Early Treatment Diabetic Retinopathy Study final scale, as the development of soft exudates and/or intraretinal microvascular abnormalities, as the development of clinically important retinopathy, or as any of the above, and was considered "early" if it occurred between baseline and 12-month follow-up visits.

Results  Early worsening was observed at the 6- and/or 12-month visit in 13.1% of 711 patients assigned to intensive treatment and in 7.6% of 728 patients assigned to conventional treatment (odds ratio, 2.06; P<.001); recovery had occurred at the 18-month visit in 51% and 55% of these groups, respectively (P=.39). The risk of 3-step or greater progression from the retinopathy level present 18 months after entry into the trial was greater in patients who previously had had early worsening than in those who had not. However, the large long-term risk reduction with intensive treatment was such that outcomes in intensively treated patients who had early worsening were similar to or more favorable than outcomes in conventionally treated patients who had not. The most important risk factors for early worsening were higher hemoglobin A_1clevel at screening and reduction of this level during the first 6 months after randomization. We found no evidence to suggest that more gradual reduction of glycemia might be associated with less risk of early worsening. Early worsening led to high-risk proliferative retinopathy in 2 patients and to clinically significant macular edema in 3; all responded well to treatment.

Conclusions  In the DCCT, the long-term benefits of intensive insulin treatment greatly outweighed the risks of early worsening. Although no case of early worsening was associated with serious visual loss, our results are consistent with previous reports of sight-threatening worsening when intensive treatment is initiated in patients with long-standing poor glycemic control, particularly if retinopathy is at or past the moderate nonproliferative stage. Ophthalmologic monitoring before initiation of intensive treatment and at 3-month intervals for 6 to 12 months thereafter seems appropriate for such patients. In patients whose retinopathy is already approaching the high-risk stage, it may be prudent to delay the initiation of intensive treatment until photocoagulation can be completed, particularly if hemoglobin A_1c is high.

From the Diabetes Control and Complications Trial Research Group, Bethesda, Md. A complete listing of the Diabetes Control and Complications Trial Research Group is published in the Archives of Ophthalmology (1995;113:49-51).

RELATED LETTER

Perioperative Glycemic Control and Diabetic Retinopathy—Reply
Chikako Suto, Sadao Hori, and Satoshi Kato
Arch Ophthalmol. 2007;125(4):578.
EXTRACT | FULL TEXT  

RELATED ARTICLE

Worsening of Diabetic Retinopathy After Improvement of Glycemic Control
Matthew D. Davis
Arch Ophthalmol. 1998;116(7):931-932.
EXTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Management of Diabetic Retinopathy: A Systematic Review
Mohamed et al.
JAMA 2007;298:902-916.
ABSTRACT | FULL TEXT  

Type 1 diabetes and pregnancy
Taylor and Davison
BMJ 2007;334:742-745.
FULL TEXT  

Perioperative Glycemic Control and Diabetic Retinopathy--Reply
Suto et al.
Arch Ophthalmol 2007;125:578-578.
FULL TEXT  

High Glucose Blunts Vascular Endothelial Growth Factor Response to Hypoxia via the Oxidative Stress-Regulated Hypoxia-Inducible Factor/Hypoxia-Responsible Element Pathway
Katavetin et al.
J. Am. Soc. Nephrol. 2006;17:1405-1413.
ABSTRACT | FULL TEXT  

The Multifocal ERG in Diabetic Patients without Retinopathy during Euglycemic Clamping
Klemp et al.
IOVS 2005;46:2620-2626.
ABSTRACT | FULL TEXT  

Screening for Retinopathy in the Pediatric Patient With Type 1 Diabetes Mellitus
Lueder et al.
Pediatrics 2005;116:270-273.
ABSTRACT | FULL TEXT  

Care of Children and Adolescents With Type 1 Diabetes: A statement of the American Diabetes Association
Silverstein et al.
Diabetes Care 2005;28:186-212.
FULL TEXT  

Interactions Between Hyperglycemia and Hypoxia: Implications for Diabetic Retinopathy
Nyengaard et al.
Diabetes 2004;53:2931-2938.
ABSTRACT | FULL TEXT  

Diabetic Retinopathy
Frank
NEJM 2004;350:48-58.
FULL TEXT  

Isolated Pancreas Transplantation for Type 1 Diabetes: A Doctor's Dilemma
Nathan
JAMA 2003;290:2861-2863.
FULL TEXT  

Diabetic Retinopathy: Contemporary prevalence in a well-controlled population
Brown et al.
Diabetes Care 2003;26:2637-2642.
ABSTRACT | FULL TEXT  

Effect of Intensive Therapy on the Microvascular Complications of Type 1 Diabetes Mellitus
The Writing Team for the Diabetes Control and Comp
JAMA 2002;287:2563-2569.
ABSTRACT | FULL TEXT  

Progression of Retinopathy in Insulin-Treated Type 2 Diabetic Patients
Henricsson et al.
Diabetes Care 2002;25:381-385.
ABSTRACT | FULL TEXT  

Response to Cundy
Nathan et al.
Diabetes Care 2001;24:795-796.
FULL TEXT  

""Seeing"" Between the Lines
Hirsch
Clin. Diabetes 2001;19:28-28.
FULL TEXT  

How Often Should Patients With Diabetes Be Screened for Retinopathy?
Javitt et al.
JAMA 2000;284:437-439.
FULL TEXT  

Coagulation pathways and diabetic retinopathy: abnormal modulation in a selected group of insulin dependent diabetic patients
Giusti et al.
Br. J. Ophthalmol. 2000;84:591-595.
ABSTRACT | FULL TEXT  

Retinopathy and Nephropathy in Patients with Type 1 Diabetes Four Years after a Trial of Intensive Therapy
The Diabetes Control and Complications Trial/Epide
NEJM 2000;342:381-389.
ABSTRACT | FULL TEXT  

Treatment of Diabetic Retinopathy
Ferris et al.
NEJM 1999;341:667-678.
FULL TEXT  

Worsening of Diabetic Retinopathy After Improvement of Glycemic Control
Davis
Arch Ophthalmol 1998;116:931-932.
FULL TEXT